Pre-clinical efforts identified improved anti-cancer effects of the combination in vitro and in animal models without specifically investigating the target cell populations sensitized to Top2 poisons by the DNA-PK inhibitors, nor the mechanism for this sensitivity. The gene discussed is PRKDC; the disease is cancer.